Wu S, et al. - Researchers tested the premise that high vimentin (VIM) expression was associated with more aggressive disease and worse outcomes in acute myeloid leukemia (AML) patients. The cancer genome atlas (TCGA) data of 173 AML subjects were analyzed for which complete clinical and expression data were available. The relationship between VIM mRNA expression and patient’s clinical and molecular characteristics, including clinical outcome, was evaluated. It was observed that overexpression of the epithelial to mesenchymal transition (EMT) marker vimentin was correlated with poor clinical outcome in older patients with cytogenetically normal AML, and could play a role in this disease.